Camille N. Abboud
Washington University in St. Louis
242 Papers
2.5K Citations
Camille N. Abboud is an academic researcher from Washington University in St. Louis. The author has contributed to research in topics: Transplantation & Medicine. The author has an hindex of 51, co-authored 233 publications. Previous affiliations of Camille N. Abboud include University of Rochester & University of California, Los Angeles.
Chat about Author
Papers
Phase I/II randomized trial evaluating the safety and clinical effects of repifermin administered to reduce mucositis in patients undergoing autologous hematopoietic stem cell transplantation.
Cesar O. Freytes,Voravit Ratanatharathorn,Charles W. Taylor,Camille N. Abboud,Nancy Chesser,Alejandro Restrepo,Jorge I. Arango,Daniel Odenheimer +7 more
TL;DR: Repifermin given before and after auto-HSCT seems to be active in reducing mucositis, but a larger trial will be necessary to determine the efficacy of repifermin with this dose schedule.
Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplants.
Aaron P. Rapoport,Luc F. Miller Watelet,Tammy Linder,Shirley Eberly,Richard F. Raubertas,Joanna Lipp,Reggie E. Duerst,Camille N. Abboud,Louis S. Constine,Jessica Andrews,Mary Ann Etter,Linda Spear,Elizabeth Powley,Charles H. Packman,Jacob M. Rowe,Ullrich Schwertschlag,Camille L. Bedrosian,Jane L. Liesveld +17 more
TL;DR: The peak oral mucositis score and the duration of parenteral nutritional support are useful indices of gastrointestinal toxicity because these end points are correlated with clinically significant events, including blood infections and treatment-related mortality.
Cladribine in the Treatment of Acute Myeloid Leukemia: A Single-Institution Experience
Michael G. Martin,John S. Welch,Kristan M. Augustin,Lindsay Hladnik,John F. DiPersio,Camille N. Abboud +5 more
TL;DR: The data suggest that cladrabine-based regimens should be further explored in both the salvage and first-line setting and might offer an attractive backbone on which to add novel therapies.
Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF.
Michael G. Martin,Kristan M. Augustin,Geoffrey L. Uy,John S. Welch,Lindsay Hladnik,Sagun D. Goyal,Divya Tiwari,Ryan Monahan,Richard M. Reichley,Amanda F. Cashen,Keith Stockerl-Goldstein,Peter Westervelt,Camille N. Abboud,John F. DiPersio,Ravi Vij +14 more
TL;DR: The addition of GO, at this dose and schedule, to FLAG‐I failed to improve the outcomes in patients with relapsed/refractory AML, and the patients who received G‐CSF concurrently with chemotherapy had improved outcomes.
High Rates of Transplantation in the Phase III Sierra Trial Utilizing Anti-CD45 (Iodine) 131I-Apamistamab (Iomab-B) Conditioning with Successful Engraftment and Tolerability in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) Patients after Lack of Response to Conventional Care and Targeted Th
Boglarka Gyurkocza,Rajneesh Nath,Stuart Seropian,Ha Yeong Choe,Mark R. Litzow,Nebu Koshy,Patrick J. Stiff,Camille N. Abboud,Benjamin Tomlinson,Sunil Abhyankar,Parameswaran Hari,George Chen,Zaid S Al-Kadhimi,Mitchell Sabloff,Johnnie J. Orozco,James M. Foran,Partow Kebriaei,Katarzyna Jamieson,Margarida De Magalhaes-Silverman,Koen van Besien,Michael W. Schuster,Arjun Datt Law,Moshe Yair Levy,Hillard M. Lazarus,Sergio Giralt,Mark S. Berger,J. Spross,Avinash Desai,Vijay Reddy,John M. Pagel +29 more